Company intelligence / Profile preview
Orcrist Bio
Calgary, Alberta, Canadaorcristbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Orcrist Bio was a Canadian biotechnology company based in Calgary that specialized in the development of stem cell-mobilizing pharmaceuticals. The company's lead program, HYC750, was a proprietary formulation of hyaluronan (HA) designed to stimulate the release of hematopoietic stem cells and neutrophils from the bone marrow into the peripheral blood. This technology was primarily aimed at treating chemotherapy-induced blood cell depletion and improving the efficiency of stem cell harvesting for transplantation. Orcrist Bio reached the Phase 1 clinical trial stage in 2009, but the company has since ceased its biotechnology operations.
- Therapeutic areas
- OncologyHematology
- Modalities
- Biologic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
MedistemInPEC BV
Beyond the preview
Go deeper on Orcrist Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Orcrist Bio.